Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169 | Director · President and CEO | February 10, 2026 | February 12, 2026 |
| Dyne Therapeutics, Inc.DYN · Entity 3948 | Director | December 22, 2025 | December 23, 2025 |
| Horizon Therapeutics Public Ltd CoHZNP · Entity 109157 | EVP & President, International | February 22, 2021 | February 23, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COLLEGIUM PHARMACEUTICAL, INC
Report date February 10, 2026 · Filed February 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 176,629 |
Reported balance
After 2026-02-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-10 · Grant · Acquired 79,264 · Balance 176,629 F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2027, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. F2: Includes 376 shares acquired on July 18, 2025 under the Issuer's employee stock purchase plan. |
| Common StockSEC Table I · non-derivative | Direct | 209,160 |
Reported balance
After 2026-02-10 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-02-10 · Grant · Acquired 32,531 · Balance 209,160 F3: Effective February 10, 2026, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 32,531 performance share units ("PSUs") granted in the Issuer's 2025 fiscal year. |
| Common StockSEC Table I · non-derivative | Direct | 197,864 |
Reported balance
After 2026-02-10 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-02-10 · Tax withholding · Disposed 11,296 · Balance 197,864 F4: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2027, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.
F2: Includes 376 shares acquired on July 18, 2025 under the Issuer's employee stock purchase plan.
F3: Effective February 10, 2026, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 32,531 performance share units ("PSUs") granted in the Issuer's 2025 fiscal year.
F4: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs.
Dyne Therapeutics, Inc.
Report date December 22, 2025 · Filed December 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.78 · Expires 2035-12-21 | Direct | 59,665 |
Reported balance
After 2025-12-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-22 · Grant · Acquired 59,665 · Balance 59,665 F1: The option was granted on December 22, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments through December 22, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on December 22, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments through December 22, 2028.
Horizon Therapeutics Public Ltd Co
Report date February 22, 2021 · Filed February 23, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 104,165 |
Ending reported balance
After 2021-02-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-02-22 · Sale · Disposed 7,713 · Balance 104,810 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2020. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.71 to $87.64 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 2 · 2021-02-22 · Sale · Disposed 645 · Balance 104,165 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2020. F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.14 to $88.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2020.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.71 to $87.64 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.14 to $88.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 23, 2019 Filed Mar 25, 2019 21:14 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 4,209 | $26.84 | $112,969.56 |
DisclosureSEC source: 0001209191-19-021270 · doc4.xml · nonDerivative · entry 2 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,154 Read SEC document |
| March 23, 2019 Filed Mar 25, 2019 21:14 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 9,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-021270 · doc4.xml · nonDerivative · entry 1 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 17:27 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 8,622 | $21.54 | $185,717.88 |
DisclosureSEC source: 0001209191-19-012703 · doc4.xml · nonDerivative · entry 2 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,863 Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 17:27 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantOrdinary Shares | 19,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-012703 · doc4.xml · nonDerivative · entry 1 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,485 F1 · kind: On January 5, 2018, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 20, 2019, the PSUs vested as to the number of shares reported above, upon the Issuer's determination that certain performance criteria had been met. F1 · shares: On January 5, 2018, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 20, 2019, the PSUs vested as to the number of shares reported above, upon the Issuer's determination that certain performance criteria had been met. Read SEC document |
| January 05, 2019 Filed Jan 8, 2019 20:41 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 17,259 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-002937 · doc4.xml · derivative · entry 4 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,520 Underlying: Ordinary Shares · 17,259 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2018. F3 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2018. Read SEC document |
| January 05, 2019 Filed Jan 8, 2019 20:41 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 7,962 | $20.39 | $162,345.18 |
DisclosureSEC source: 0001209191-19-002937 · doc4.xml · nonDerivative · entry 2 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,471 Read SEC document |
| January 05, 2019 Filed Jan 8, 2019 20:41 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 17,259 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-002937 · doc4.xml · nonDerivative · entry 1 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 20:41 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units (RSU) · Derivative | 53,948 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-002937 · doc4.xml · derivative · entry 3 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,948 Underlying: Ordinary Shares · 53,948 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2019. F2 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2019. Read SEC document |
| July 31, 2018 Filed Aug 1, 2018 21:05 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 5,675 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-044823 · doc4.xml · derivative · entry 3 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,675 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. The restricted stock units vest 25% annually on each anniversary of the vesting commencement date (July 31, 2014). F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. The restricted stock units vest 25% annually on each anniversary of the vesting commencement date (July 31, 2014). Read SEC document |
| July 31, 2018 Filed Aug 1, 2018 21:05 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 1,663 | $17.63 | $29,318.69 |
DisclosureSEC source: 0001209191-18-044823 · doc4.xml · nonDerivative · entry 2 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,174 Read SEC document |
| July 31, 2018 Filed Aug 1, 2018 21:05 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 5,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-044823 · doc4.xml · nonDerivative · entry 1 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · balance_after: Includes 2,371 ordinary shares of the Issuer acquired by the reporting person on June 1, 2018 pursuant to an employee stock purchase program. Read SEC document |
| May 03, 2018 Filed May 7, 2018 20:46 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units (RSU) · Derivative | 51,779 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-028489 · doc4.xml · derivative · entry 1 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,779 Underlying: Ordinary Shares · 51,779 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F2 · date: The RSU's were approved by the Issuer's Compensation Committee on January 5, 2018, subject to shareholder approval of certain amendments to the Issuer's 2014 Equity Incentive Plan (the "Plan") under which the RSU's were granted. The Issuer's shareholders approved the amendments to the Plan on May 3, 2018. F3 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2018. F1 · derivative.expiration_date: Each RSU represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 17:34 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 9,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-021796 · doc4.xml · derivative · entry 3 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Underlying: Ordinary Shares · 9,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: On March 23, 2015, the reporting person was granted 38,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: On March 23, 2015, the reporting person was granted 38,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 17:34 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 4,209 | $13.86 | $58,336.74 |
DisclosureSEC source: 0001209191-18-021796 · doc4.xml · nonDerivative · entry 2 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,791 Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 17:34 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 9,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-021796 · doc4.xml · nonDerivative · entry 1 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| July 31, 2017 Filed Jul 31, 2017 19:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 5,675 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-046817 · doc4.xml · derivative · entry 3 Karnani Vikram · CIK 0001699488 · SVP, Rheumatology Bus. Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,675 Underlying: Ordinary Shares · 5,675 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. The restricted stock units vest 25% annually on each anniversary of the vesting commencement date (July 31, 2014). F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. The restricted stock units vest 25% annually on each anniversary of the vesting commencement date (July 31, 2014). Read SEC document |
| July 31, 2017 Filed Jul 31, 2017 19:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 2,662 | $11.98 | $31,890.76 |
DisclosureSEC source: 0001209191-17-046817 · doc4.xml · nonDerivative · entry 2 Karnani Vikram · CIK 0001699488 · SVP, Rheumatology Bus. Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Read SEC document |
| July 31, 2017 Filed Jul 31, 2017 19:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 5,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-046817 · doc4.xml · nonDerivative · entry 1 Karnani Vikram · CIK 0001699488 · SVP, Rheumatology Bus. Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · balance_after: Includes 1,428 ordinary shares of the Issuer acquired by the reporting person on June 1, 2017 pursuant to an employee stock purchase program. Read SEC document |
| March 23, 2017 Filed Mar 24, 2017 18:30 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 9,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-022837 · doc4.xml · derivative · entry 3 Karnani Vikram · CIK 0001699488 · SVP, Rheumatology Bus. Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Ordinary Shares · 9,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: On March 23, 2015, the reporting person was granted 38,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: On March 23, 2015, the reporting person was granted 38,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| March 23, 2017 Filed Mar 24, 2017 18:30 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 2,955 | $14.56 | $43,024.80 |
DisclosureSEC source: 0001209191-17-022837 · doc4.xml · nonDerivative · entry 2 Karnani Vikram · CIK 0001699488 · SVP, Rheumatology Bus. Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,059 Read SEC document |
| March 23, 2017 Filed Mar 24, 2017 18:30 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 9,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-022837 · doc4.xml · nonDerivative · entry 1 Karnani Vikram · CIK 0001699488 · SVP, Rheumatology Bus. Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.